Literature DB >> 7258121

Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy.

L L Bartel, J L Hussey, E Shrago.   

Abstract

Serum carnitine levels in nondialyzed and dialyzed patients with chronic renal disease were compared against a group of normal control subjects. The concentration of serum carnitine was directly correlated with that of serum creatinine (r = +0.734; p less than 0.001). In nondialyzed uremic patients the serum free carnitine levels in males rose 218% (p less than 0.001) and in females rose 186% (p less than 0.001) above normal control values. During dialysis there was a sharp decline in serum carnitine to levels reaching 20% of the zero time control value (p less than 0.001). The decrease in serum carnitine could be accounted for by an almost quantitatively accumulation of carnitine in the dialysate fluid. After termination of dialysis there was a hyperbolic rise in serum carnitine which reached the high values again within 44 to 48 h. It is postulated that frequent perturbations in serum carnitine as a result of chronic dialysis therapy over a prolonged time period could potentially lead to a tissue deficiency in carnitine with its resultant complications.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7258121     DOI: 10.1093/ajcn/34.7.1314

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

1.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

2.  Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.

Authors:  Jan Rasmussen; Olav W Nielsen; Nils Janzen; Morten Duno; Hannes Gislason; Lars Køber; Ulrike Steuerwald; Allan M Lund
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial.

Authors:  Lucile Mercadal; Mathieu Coudert; Anne Vassault; Laurence Pieroni; Alain Debure; Messaoud Ouziala; Hélène Depreneuf; Christine Fumeron; Aude Servais; Nader Bassilios; Jacques Bécart; Ubald Assogba; Mahmoud Allouache; Boussad Bouali; Nhan Luong; Marie Paul Dousseaux; Sophie Tezenas-du Montcel; Gilbert Deray
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 8.237

Review 5.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  [Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function].

Authors:  M Leschke; K W Rumpf; T Eisenhauer; K Becker; U Bock; F Scheler
Journal:  Klin Wochenschr       Date:  1984-03-15

Review 7.  Nutritional management of children with chronic renal failure. Summary of the task force on nutritional management of children with chronic renal failure.

Authors:  S Hellerstein; M A Holliday; W E Grupe; R N Fine; R S Fennell; R W Chesney; J C Chan
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

8.  Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome.

Authors:  I Bernardini; W B Rizzo; M Dalakas; J Bernar; W A Gahl
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

9.  Carnitine plasma concentrations in 353 metabolically healthy children.

Authors:  E Schmidt-Sommerfeld; D Werner; D Penn
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

Review 10.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.